Francesco De Sanctis

List of Publications by Year
in descending order

41 papers	1,964 citations	361413 20 h-index	345221 36 g-index
45 all docs	45 docs citations	45 times ranked	3891 citing authors

#	Article	IF	Citations
1	Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. Journal of Clinical Investigation, 2015, 125, 3365-3376.	8.2	443
2	Baricitinib restrains the immune dysregulation in patients with severe COVID-19. Journal of Clinical Investigation, 2020, 130, 6409-6416.	8.2	213
3	Monocytes in the Tumor Microenvironment. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 93-122.	22.4	126
4	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. , 2019, 7, 255.		123
5	Deciphering the state of immune silence in fatal COVID-19 patients. Nature Communications, 2021, 12, 1428.	12.8	107
6	The dark side of tumor-associated endothelial cells. Seminars in Immunology, 2018, 35, 35-47.	5.6	82
7	MDSCs in cancer: Conceiving new prognostic and therapeutic targets. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 35-48.	7.4	68
8	The Endless Saga of Monocyte Diversity. Frontiers in Immunology, 2019, 10, 1786.	4.8	67
9	Tumor endothelial marker 1â€“specific DNA vaccination targets tumor vasculature. Journal of Clinical Investigation, 2014, 124, 1497-1511.	8.2	59
10	The Emerging Immunological Role of Post-Translational Modifications by Reactive Nitrogen Species in Cancer Microenvironment. Frontiers in Immunology, 2014, 5, 69.	4.8	58
11	The Engagement Between MDSCs and Metastases: Partners in Crime. Frontiers in Oncology, 2020, 10, 165.	2.8	50
12	Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. OncoImmunology, 2017, 6, e1326442.	4.6	48
13	Induction of immunosuppressive functions and NF-ÎºB by FLIP in monocytes. Nature Communications, 2018, 9, 5193.	12.8	45
14	Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages. Cancer Discovery, 2020, 10, 1758-1773.	9.4	44
15	Methods to Measure MDSC Immune Suppressive Activity In Vitro and In Vivo. Current Protocols in Immunology, 2019, 124, e61.	3.6	35
16	Arginase 1â€“Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Antiâ€“PD-1 Checkpoint Blockade. Cancer Immunology Research, 2021, 9, 1316-1326.	3.4	32
17	Overview of the optical properties of fluorescent nanoparticles for optical imaging. European Journal of Histochemistry, 2017, 61, 2830.	1.5	31
18	Tumor-Induced Myeloid-Derived Suppressor Cells. Microbiology Spectrum, 2016, 4, .	3.0	28

#	Article	IF	Citations
19	Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. Scientific Reports, 2019, 9, 12286.	3.3	27
20	Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies. Cancer Research, 2016, 76, 2540-2551.	0.9	25
21	Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer. , 2021, 9, e002876.		25
22	A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment. Cells, 2021, 10, 2700.	4.1	25
23	A Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma. Journal of Immunology, 2015, 195, 4020-4027.	0.8	24
24	Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. , 2022, 10, e003549.		22
25	Targeting tumor vasculature: expanding the potential of DNA cancer vaccines. Cancer Immunology, Immunotherapy, 2015, 64, 1339-1348.	4.2	19
26	Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. Oncotarget, 2017, 8, 86987-87001.	1.8	18
27	Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis. Cell Death and Differentiation, 2022, 29, 420-438.	11.2	14
28	Tâ€cell tracking using Cerenkov and radioluminescence imaging. Journal of Biophotonics, 2018, 11, e201800093.	2.3	13
29	Tandem Dye-Doped Nanoparticles for NIR Imaging via Cerenkov Resonance Energy Transfer. Frontiers in Chemistry, 2020, 8, 71.	3.6	13
30	The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia. Stem Cell Research and Therapy, 2021, 12, 316.	5.5	12
31	Hyperthermic treatment at 56â€Â°C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens. Vaccine, 2018, 36, 3708-3716.	3.8	11
32	Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo. Frontiers in Cell and Developmental Biology, 2020, 8, 308.	3.7	8
33	Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. Journal of Immunology Research, 2022, 2022, 1-21.	2.2	6
34	Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma. Immunology, 2015, 146, 33-49.	4.4	5
35	Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. Carcinogenesis, 2018, 39, 1197-1206.	2.8	5
36	Anti-telomerase T cells adoptive transfer. Aging, 2017, 9, 2239-2240.	3.1	5

#	Article	IF	Citations
37	Optical emission of ²²³Radium: in vitro and in vivo preclinical applications. Journal of Biophotonics, 2018, 11, e201700209.	2.3	3
38	Maternal Phylogenetic Relationships and Genetic Variation among Rare, Phenotypically Similar Donkey Breeds. Genes, 2021, 12, 1109.	2.4	3
39	Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies. Frontiers in Genetics, 2022, 13, .	2.3	3
40	How to Reprogram Myeloma-Associated Macrophages: Target IKZF1. Cancer Immunology Research, 2021, 9, 254-254.	3.4	2
41	Tumor-Induced Myeloid-Derived Suppressor Cells. , 0, , 833-856.		1